Immunocore Holdings plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
13analysts covering
FY Revenue (est.)
$464.6Mnext fiscal year
FY EPS (est.)
-$0.02next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
KIMMTRAK Net Product Sales Quarterly106.7MTarget: Continued global expansion and community penetration in metastatic uveal melanoma
Cash, Cash Equivalents and Marketable Securities Quarterly844.9MTarget: Maintain strong balance sheet to fund Phase 3 trials and pipeline expansion
Diluted Earnings Per Share (EPS) Quarterly0.3Target: Achieve sustainable profitability through commercial growth and disciplined spending
Watch Items
- TEBE-AM Phase 3 Trial Enrollment and Data ReadoutTrigger: Enrollment completion in 1H 2026; topline data readout as early as 2H 2026Action: Monitor clinical trial updates and regulatory filings for second-line cutaneous melanoma
- Brenetafusp (PRAME) Phase 1/2 Combination DataTrigger: Presentation of clinical data highlighting brenetafusp's potential in PD-1 resistant diseaseAction: Evaluate efficacy signals and dose selection for future registrational trials
- Autoimmune Pipeline Progress (IMC-S118AI & IMC-U120AI)Trigger: Initiation of first-in-human trials for IMC-S118AI in Type 1 DiabetesAction: Track platform expansion milestones beyond oncology into autoimmune indications
Research as of 20 Jun 2026